Sysmex

Skip Navigation

SearchMenu

About Sysmex

Press Releases

Management & Business Management & Business
May. 08, 2018

Sysmex to Establish Bio-Diagnostic Reagent Center
Reinforcing Our Diagnostic Reagent Development and Production Function by Establishing a Location to Handle Integrated Development through Production and Distribution of Bio-Diagnostic Reagents

Sysmex Corporation (HQ: Kobe, Japan; Chairman and CEO: Hisashi Ietsugu) announces plans to establish the Bio-Diagnostic Reagent Center to boost the Company’s competitiveness and provide a stable supply of “diagnostic reagents using proteins and substances derived from living organisms” (bio-diagnostic reagents) by handling the integrated process from procurement of substances, and the development, production to distribution of bio-diagnostic reagents. Through this facility, Sysmex aims to expand its activities related to the fields of hemostasis, immunochemistry, life science and others.

To promote the sustainable growth of the Sysmex Group and strengthen the management foundation that underlies it, Sysmex aims to achieve further growth in the Company’s core businesses in the fields of hematology, urinalysis, hemostasis and immunochemistry. In addition, we aim to monetize businesses centering on the life science field.

With a view to strengthening its business in the hemostasis, immunochemistry, life science and other fields, the Company will boost product competitiveness in bio-diagnostic reagents and provide a stable supply of these reagents. We will establish this center, which will handle integrated process from substance procurement, development, production to distribution of bio-diagnostic reagents, with operations slated to commence in April 2019, in Seishin Industrial Park (Nishi-ku, Kobe). This location adjoins Technopark, our R&D hub.

By establishing this center, Sysmex plans to undertake the proprietary development of diverse substances, including cell cultures, silkworm-generated recombinant proteins, and microbial gene recombinant proteins, ensuring a stable supply of these substances. In collaboration with the nearby Sysmex Technopark, at the new center Sysmex aims to accelerate the development of new testing parameters and integrate technological development of diagnostic reagents, from development to prototyping and mass production. As a result, the Company intends to speed the market introduction of diagnostic reagents of even more stable quality.

In addition, we expect to greatly reduce production lead times by promoting the digitization of production and distribution, and advanced, automated equipment arranged in an optimal layout. The center’s production will be linked with market consumption of diagnostic reagents, and we will strengthen links with various supply chain functions. As a result, we will reinforce our structure for swiftly providing a stable supply of high-quality bio-diagnostic reagents.

Going forward, Sysmex will continue providing a stable supply of high-quality, high-value-added products to its customers around the world as it contributes to people’s health.  

Overview of the Bio-Diagnostic Reagent Center
  Location: Takatsukadai, Nishi-ku, Kobe, Hyogo Prefecture, Japan
  Site area: Approx. 29,400㎡
  Floor space: Approx. 41,000㎡
  Investment: ¥18.0 billion
  Environmental considerations: The facility will be built to incorporate environmental considerations, integrated in an architectural design incorporating eaves and louvers to lower the heat load. 
The facility will have high-efficiency electrical and air conditioning equipment, as well as a heat-recovery type high-efficiency air conditioning system, that are energy-saving and meet the standards of Japan’s Top Runner program.
Sysmex plans to acquire the “S Rank” under the city of Kobe’s Comprehensive Assessment System for Built Environment Efficiency (CASBEE Kobe).
  Start of operations: April 2019

 
 

Artist’s rendition of the Bio-Diagnostic Reagent Center

   
     
 

*Information contained in the press release is current as of the date of the announcement,
but may be subject to change without prior notice.

Back to "Press Releases"